|
|
||||||||
1 Quebec Heart Institute and Department of Medicine, Faculty of Medicine, Laval University, Ste-Foy, Quebec G1K 7P4; and 2 Laboratory of Molecular Endocrinology, Centre Hospitalier de l'Université Laval, Ste-Foy, Quebec, Canada G1V 4G2
| |
ABSTRACT |
|---|
|
|
|---|
Estrogen replacement
therapy reduces risk of cardiovascular events by altering coronary
vasoregulation and distribution of blood flow. Vessel reactivity and
blood flow distribution were assessed in anesthetized female rabbits in
the following groups: 1) sham, 2) ovariectomy,
3) ovariectomy + 17
-estradiol, and
4) ovariectomy + dehydroepiandrosterone. After a
2-wk treatment, cardiac hemodynamics, vascular reserve, and blood
flow were evaluated during the following infusions: 1) NaCl,
or vehicle (0.5 ml/min), 2) acetylcholine (2 mg/kg),
3) isoproterenol (2 mg · kg
1 · min
1), and
4) chromonar (8 mg/kg). In hearts from ovariectomized
rabbits, autoregulatory blood flow was preserved despite lower
diastolic perfusion pressures (55 ± 8 vs. 64 ± 8 mmHg
in sham) and rate-pressure product (14.4 ± 0.8 vs. 19.3 ± 0.8 beats/min · mmHg×10
3). Estrogen
replacement therapy restored coronary pressure and reserve, and all
drugs increased vascular conductance. In conclusion, in hearts from
ovariectomized rabbits, vascular reserve declined because coronary
pressure was lower; however, blood flow was preserved at a higher level
than expected for oxygen demand. Estrogen replacement therapy restores
myocardial oxygen supply-demand indices and returns coronary
pressure-flow data to levels observed in animals with intact ovaries.
ovariectomy; vasoregulation
| |
INTRODUCTION |
|---|
|
|
|---|
THE INCIDENCE OF
ADVERSE CARDIOVASCULAR events in women increases substantially
after menopause (31, 42). Estrogen replacement therapy
(ERT) in postmenopausal women has been shown to reduce the incidence of
adverse coronary events and associated mortality (7) but
not the risk of stroke (38). In women with confirmed coronary artery disease, treatment with 17
-estradiol
(E2
) results in a significant improvement of exercise
duration (34). Other benefits that could contribute to
vascular protection in women include improvement in serum lipid
profiles (2). However, many studies support the hypothesis
that estrogen has a direct influence on regulation of vascular function
(11, 18) and intracellular signaling pathways in vascular
smooth muscle (16, 27). Chronic (26, 28) and
acute (8, 40) administration of E2
improves vasorelaxation via either endothelium-dependent (19, 44)
or -independent mechanisms (6, 17). Furthermore, estrogen
therapy has been reported to significantly reduce myocyte injury
(10) and the incidence of arrhythmias during
ischemia-reperfusion injury (29).
Other steroids such as dehydroepiandrosterone (DHEA) and its sulfate may influence vasoregulation but they have not been well studied. DHEA therapy may attenuate progression or development of vascular disease (13) because it may be a precursor of estrogen and androgen in tissues. Greater serum DHEA levels have been associated with several major cardiovascular risk factors; however, they appear to be unrelated to the risk of fatal cardiovascular events in women (3).
There is accumulating evidence that ERT modulates multiple mechanisms
within the vessel wall that contribute to vasoregulation. Accordingly,
we studied distribution of myocardial blood flow in
cycling/ovariectomized (Ovx) rabbits treated with either
E2
or DHEA and during vascular challenge with either
endothelium-dependent or -independent agonists.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
All procedures used in the present study are in accordance with the "Guide to the Care and Use of Experimental Animals" of the Canadian Council on Animal Care. The Laval University Animal Ethics Committee also approved these studies.
Female New Zealand White rabbits (2.2-2.7 kg body wt) obtained from Charles River Laboratories were used in these studies. The rabbits were acclimatized for several days in our animal housing facilities with free access to food and water and were kept on a strict 12:12-h dark-light cycle.
Drugs.
Acetylcholine (ACh), isoproterenol (Iso), E2
, and DHEA
were purchased from Sigma (St. Louis, MO). Chromonar (Chr), a selective coronary vasodilator, was a generous gift from Aventis. All drugs were
prepared fresh on the day of the study and were dissolved in saline.
Surgical preparation.
Rabbits were premedicated with acepromazine maleate (5 mg/kg im) and
anesthetized with intravenous pentobarbitone sodium (25 mg/kg).
Butorphanol (0.22 mg/kg im) was administered for analgesia. The
ovariectomy was performed via a bilateral ventral incision as
previously described (24); incisions were closed in layers with sutures. Sham animals were handled in the same way as Ovx animals,
with the exception that ovaries were not removed. E2
or
DHEA was administered with the use of subcutaneous implants (2.0 cm × 1.4 mm and 5.0 cm × 1.65 mm, respectively) positioned in the ventrolateral region. Implants were made from Silastic tubing
and packed with crystalline E2
or crystalline DHEA;
tubing was plugged with silicone adhesive. These Silastic implants have previously been used for constant release and maintenance of uniform circulating levels of estrogens (22); empty implants were
used as placebo.
and DHEA. Rabbits were intubated and mechanically ventilated with a mixture of
25% oxygen-75% room air by using a positive-pressure small animal
ventilator (MDI; Mobile, AL); respiratory rate and tidal volume were
adjusted to maintain arterial blood gases within physiological values.
The chest was opened via a left thoracotomy; Silastic catheters were
positioned in the aorta via the left internal carotid artery for
measurement of arterial blood pressure and withdrawal of reference
blood samples for the radioactive microsphere technique. A double-lumen
Silastic catheter was inserted into the left atrium for drug infusions
and injection of radioactive microspheres.
Experimental protocol.
The following four groups were studied: 1) sham (i.e.,
cycling females), 2) Ovx, 3) Ovx + E2
, and 4) Ovx + DHEA.
1 · min
1), and
4) Chr (8 mg/kg bolus). Drug dosages were determined from preliminary experiments in our laboratory (data not shown). ACh was
used to assess endothelium-dependent vasodilatation, Iso was used to
assess metabolic-induced vasodilatation, and Chr was used to produce
maximal pharmacological vasodilatation via endothelium-independent mechanisms (43). The same sequence of drug administration
was replicated in each experiment; Chr was administered last because of
its long-lasting and maximal pharmacological vasodilatory effects.
At the end of the experiment, a supplemental dose of pentobarbital
sodium was administered to ensure profound anesthesia; saturated KCl
was then injected intra-atrially to arrest the heart during diastole.
The heart was removed and fixed by immersion in 10% (vol/vol) neutral
formalin. After the heart was fixated, fat and valvular tissues were
trimmed away. The atria were removed and the ventricles and septum were
divided into subendocardial (Endo) and subepicardial (Epi) tissue
layers. Radioactivity was measured as previously described
(20).
Measurements of steroids. Determination of steroids was performed as previously described (4). For blood samples, 5 ml of ethanol were added to 1 ml of plasma and centrifuged at 2,000 g for 15 min. To maximize steroid recovery, the resulting pellet was further washed with 2 ml of ethanol and then centrifuged; the two extracts were combined and evaporated with nitrogen. Unconjugated steroids were separated by C-18 column (Bond Elut, Amersham; Bucks, UK) chromatography; columns were conditioned by successive passage of 10 ml methanol, 10 ml water, and 10 ml methanol-water (5:95; solution A). Extracts were solubilized in 2 ml of solution A and deposited on the column. After the C-18 column was washed with 2 ml of solution A, 5 ml of methanol-water (40:60) were added to elute the glucuronide and sulfate derivatives. The addition of 5 ml of methanol-water (85:15) enabled the elution of nonconjugated steroids. Both fractions were completely evaporated (Speed-Vac Evaporator; Savant Instruments; Farmingdale, NY). Unconjugated steroids were then solubilized in 1 ml of isooctane-toluene-methanol (90:5:5) and deposited on Sephadex LH-20 columns (Pharmacia; Uppsala, Sweden). Steroids were measured by specific radioimmunoassay with rabbit antibodies; radioimmunoassay data were analyzed as described previously (33).
Calculations and data analysis.
Transmural myocardial blood flow was expressed in
ml · min
1 · 100 g
1. Maximal
coronary conductance
(ml · min
1 · mmHg
1) was
calculated as the quotient of blood flow (ml/min) and diastolic aortic
pressure (mmHg) during pharmacologically induced vasodilatation. Cardiac output (CO; ml/min) was determined using the microsphere method
(1) and calculated using the equation CO = I(Qar/Iar), where I is the amount of radioactivity initially injected,
Qar is the blood flow of the arterial reference
sample, and Iar is the radioactivity in the
arterial reference sample. A good correlation with other dye techniques
and the microsphere method has previously been reported
(12).
3), calculated as the
product of systolic aortic pressure and heart rate, was used as an
index of myocardial oxygen demand.
Differences in cardiac hemodynamic and myocardial blood flow between
groups and interventions were assessed by analysis of variance with an
interaction effect. The Student-Newman-Keuls multiple-range test, with
0.05, was performed on all main-effect means to locate
significant differences within groups and interventions. Normality and
variance assumptions were fulfilled. P
0.05 was used
to confer statistical significance. Analyses were performed using the
SAS statistical package (SAS Institute; Cary, NC). Data are presented
as means ± SE.
| |
RESULTS |
|---|
|
|
|---|
Animal population.
Thirty-nine rabbits were entered into the study. Five rabbits died
during surgical preparation and were not included in the data analysis.
Data are presented for nine rabbits in the Ovx + E2
and Ovx + DHEA treatment groups, respectively; eight rabbits are
included in the sham and Ovx groups, respectively.
Biochemical determinations.
Plasma estradiol levels were measured in an additional series of
rabbits; in Ovx rabbits, plasma estradiol levels were lower than in the
sham group (95 ± 5 vs. 144 ± 31 pmol/l). Plasma estradiol levels were higher in Ovx + E2
(579 ± 40 vs.
144 ± 31 pmol/l in sham; P = 0.001) and Ovx + DHEA (184 ± 34 vs. 144 ± 31 pmol/l in sham;
P = 0.001) rabbits; in fact, supraphysiological plasma estradiol levels were achieved with E2
treatment. Plasma
DHEA levels were also significantly greater in Ovx + DHEA rabbits
(23 ± 1 nmol/l) compared with the Ovx + E2
group (0.6 ± 0.1 nmol/l; P = 0.001); these data
indicate that treatment with DHEA restores plasma estradiol levels to
near-normal physiological values for the rabbit. Androgen (i.e.,
testosterone) levels were not determined in these studies.
Cardiac hemodynamics.
Cardiac hemodynamic data for each experimental group and intervention
are summarized in Table 1. Heart rate was
slower (P = 0.001) in Ovx compared with sham; it was
similar in Ovx + E2
and Ovx + DHEA groups but
faster than in both sham and Ovx groups. During Iso, heart rate
increased significantly (compared with baseline values with Veh); this
parameter decreased to near baseline values after administration of
Chr. Aortic blood pressure during systole was lower (P = 0.001) in Ovx compared with sham; it was similar in Ovx + E2
and Ovx + DHEA groups but significantly
different from both sham and Ovx groups. Aortic blood pressure during
systolic was lower than Veh (P = 0.001) during ACh,
Iso, and Chr interventions. CO was less in Ovx (P = 0.003) compared with all other groups; no significant differences in CO
were observed during each pharmacological intervention. Aortic blood
pressure during diastole (i.e., coronary perfusion pressure) was lower
(P = 0.001) in Ovx compared with the other groups;
coronary perfusion pressure was significantly reduced (compared to Veh)
during ACh and Iso and was further reduced during Chr
(P = 0.001 compared with Veh, ACh, and Iso). Heart rate-arterial blood pressure product, an index of myocardial oxygen demand, is shown in Fig. 1 and was
significantly lower in Ovx compared with the other groups; treatment
with either E2
or DHEA restored heart rate-arterial
blood pressure product to levels observed in the sham group.
|
|
Distribution of myocardial blood flow.
During autoregulation (i.e., administration of Veh), myocardial blood
flow was not different between groups, as shown in Fig. 2, top; diastolic perfusion
pressure in Ovx rabbits was significantly lower than sham but restored
to baseline values after either E2
or DHEA treatments.
The leftward shift to a lower coronary perfusion pressure on the
pressure-flow curve in Ovx rabbits would suggest reduced vascular
reserve in this group (35). Pharmacological intervention
with ACh and Iso shifted the coronary perfusion pressure values towards
the line of maximal pharmacological vasodilatation obtained
with Chr (line shown in Fig. 2, top).
|
or DHEA induced a rightward shift on the Endo/Epi diastolic aortic pressure curve. Vasodilatation induced by ACh shifted the Endo/Epi leftward towards the autoregulatory break point. With the use of Iso,
Endo/Epi and diastolic aortic pressure were reduced; these data points
fall directly on the line of maximal vasodilatation obtained with Chr.
Recruitable coronary vascular reserve was available to each group
because coronary vascular conductance increased significantly during
ACh, Iso, and Chr (ACh < Iso < Chr), as shown in Fig.
3. Coronary vascular conductance was
higher (P = 0.03) in Ovx than in sham animals and was
restored to near-baseline values with either E2
or DHEA
treatment.
|
| |
DISCUSSION |
|---|
|
|
|---|
The incidence of cardiovascular disease in women increases
significantly after menopause; ERT is widely considered to be
cardioprotective (30, 40). DHEA has been reported
(21, 41) as being catabolized to either androgen or
estrogen by various enzymes (i.e., 3
-hydroxysteroid dehydrogenase/
4-
5 isomerase,
17
-hydroxysteroid dehydrogenase, 5
-reductase, and aromatase) in
animals and humans. The cardiac effects of DHEA are not well described.
The salient finding of the present in vivo study is that coronary
vascular reserve is present but significantly reduced in untreated Ovx
rabbits. Coronary pressure-flow data from this group are shifted
towards a lower coronary perfusion pressure limit during
autoregulation. This is probably because blood flow remains unchanged
despite the reduced myocardial demand indices in this group. We also
observed a higher level of coronary vascular conductance in Ovx
rabbits; possible explanations for these results include reduced
extravascular compressive forces in relation to the lower heart rate,
arterial pressure, and CO (Table 1) and altered vascular receptor
sensitivity to autacoids (25). Chronic administration of
either E2
or DHEA after oophorectomy were equally
efficient in restoring the oxygen supply-demand equilibrium and shifted coronary pressure-flow data to levels observed in animals with intact
ovaries. Alterations in the autoregulatory plateau are known to occur
in relation to adjustments in left ventricular pressure and volume
(36).
The physiological actions of E2
are probably
produced by receptor-mediated effects because functional estrogen
receptors are present in both endothelial and vascular smooth muscle
(23, 32). Estrogen also affects gene expression of cardiac
growth factors and cytokines after myocardial infarction possibly via an endothelin-mediated mechanism; upregulation of myocardial endothelin
-type receptors with estrogen treatment has been shown
(37) after ischemia-reperfusion injury.
Cardioprotective effects of E2
appear to involve
multiple mechanisms, including enhanced synthesis of nitric oxide via
nitric oxide synthase (15), a calcium channel blocker
effect (14), inhibition of vascular smooth muscle
2-adrenergic responses (9), increased
synthesis of prostaglandins (5), and activation of intracellular signaling mechanisms (i.e., cGMP-dependent
phosphorylation) (45). In the present study, circulating
estradiol levels after DHEA remained within the range of control
animals (~100 pmol/l), whereas in E2
-treated animals,
serum estradiol levels reached supraphysiological levels (~600
pmol/l). The positive cardioprotective effect of DHEA may be due to
direct conversion to estradiol within tissues.
In vivo studies in dogs have shown that acute intracoronary
administration of supraphysiological doses of estrogen induces dilation
of conductance and resistance vessels. This vasodilatory effect is
likely to be endothelium independent, mediated by a direct nongenomic
effect (i.e., ATP-sensitive K+ and/or Ca2+
channels) different from classic intracellular estrogen receptors (39). Immediate vasodilator effects of acute estrogen are
observed when plasma levels are >0.1 µM/l; physiological levels of
estrogen in the plasma are between 100 and 500 pmol/l (plasma
E2
levels were >500 pmol/l in the present study).
The long-term effects of estrogen therapy on myocardial blood flow distribution in normal coronary vessels in vivo remain poorly defined. In the present study, the maximal pharmacological vasodilatation observed during Chr occurred within the Epi tissue layer. These results suggest that the Endo tissue layer was already maximally vasodilated; this phenomenon may be inherent in this animal species. Although blood flow in the endocardium was preserved, higher blood flow levels in this tissue layer may not have been achievable due to the substantial reduction in perfusion pressure.
In conclusion, hearts from Ovx rabbits function at lower levels on the
myocardial oxygen supply-demand relation; coronary vascular reserve is
present but significantly reduced because coronary pressure-flow data
are shifted toward the lower pressure limit of autoregulation. This may
be due to preserved myocardial blood flow, although myocardial oxygen
demand indices are lower. ERT with either E2
or DHEA
restores the myocardial oxygen supply:demand relation to normal levels
and shifts coronary pressure-flow data to levels observed in animals
with intact ovaries. Whether these beneficial effects are mediated by
specific vascular estrogen receptor subtypes should be examined in
future studies.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Serge Simard for statistical analyses and Nathalie Rodrigue and Lynn Atton for technical assistance.
| |
FOOTNOTES |
|---|
This study was supported by a grant from the Heart and Stroke Foundation of Canada and by Medical Research Council of Canada Grant MT-13664. A. Dagnault was supported by a Medical Scientist fellowship from the Heart and Stroke Foundation of Canada.
Address for reprint requests and other correspondence: J. R. Rouleau, Laval Univ. and Quebec Heart Institute, Laval Hospital, 2725 Chemin Ste-Foy, Ste-Foy, Quebec, Canada G1V 4G5 (E-mail: jacques-r.rouleau{at}med.ulaval.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 2 April 2001; accepted in final form 27 May 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Archie, JP, Jr,
Fixler DE,
Ullyot DJ,
Hoffman JI,
Utley JR,
and
Carlson EL.
Measurement of cardiac output with and organ trapping of radioactive microspheres.
J Appl Physiol
35:
148-154,
1973
2.
Barrett-Conner, E,
and
Bush TL.
Estrogen and coronary heart disease in women.
J Am Med Assoc
265:
1861-1867,
1991[Abstract].
3.
Barrett-Conner, E,
and
Goodman-Gruen D.
The epidemiology of DHEAS and cardiovascular disease.
Ann NY Acad Sci
774:
259-270,
1995[ISI][Medline].
4.
Bélanger, A,
Candas B,
Dupont A,
Cusan L,
Diamond P,
Gomez JL,
and
Labrie F.
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men.
J Clin Endocrinol Metab
79:
1086-1090,
1994[Abstract].
5.
Chang, WC,
Nakao J,
Orimo H,
and
Murota SI.
Stimulation of prostacyclin biosynthetic activity by estradiol in rat aortic smooth muscle cells in culture.
Biochim Biophys Acta
619:
107-118,
1980[Medline].
6.
Davidge, ST,
and
Zhang Y.
Estrogen replacement suppresses a prostaglandin H synthase-dependent vasoconstrictor in rat mesenteric arteries.
Circ Res
83:
388-395,
1998
7.
Ettinger, B,
Friedman GD,
Bush T,
and
Quesenberry CP.
Reduced mortality associated with long-term postmenopausal estrogen therapy.
Obstet Gynecol
87:
6-12,
1996[Abstract].
8.
Gilligan, DM,
Quyyumi AA,
and
Cannon RO.
Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women.
Circulation
89:
2545-2551,
2001
9.
Gisclard, V,
Flavahan NA,
and
Vanhoutte PM.
Alpha adrenergic responses of blood vessels of rabbits after ovariectomy and administration of 17-
-estradiol.
J Pharmacol Exp Ther
240:
466-470,
1987
10.
Hale, SL,
Birnbaum Y,
and
Kloner RA.
Estradiol, administered acutely, protects ischemic myocardium in both female and male rabbits.
J Cardiovasc Pharmacol Ther
2:
47-52,
1997.
11.
Hayashi, T,
Fukuto JM,
Ignarro LJ,
and
Chaudhuri G.
Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis.
Proc Natl Acad Sci USA
89:
11259-11263,
1992
12.
Hoffbrand, BI,
and
Forsyth RP.
Validity studies of the radioactive microsphere method for the study of the distribution of cardiac output, orn blood flow, and resistance in the conscious rhesus monkey.
Cardiovasc Res
3:
426-432,
1969
13.
Ishihara, F,
Hiramatsu K,
Shigematsu S,
Aizawa T,
Niwa A,
Takasu N,
Yamada T,
and
Matsuo K.
Role of adrenal androgens in the development of arteriosclerosis as judged by pulse wave velocity and calcification of the aorta.
Cardiology
80:
332-338,
1992[ISI][Medline].
14.
Jiang, C,
Poole-Wilson PA,
Sarrel PM,
Mockizuki S,
Collins P,
and
MacLeod KT.
Effect of 17-
-oestradiol on contraction, calcium current and intracellular free calcium in guinea-pig isolated cardiac myocytes.
Br J Pharmacol
106:
739-745,
1992[ISI][Medline].
15.
Joswig, M,
Hach-Wunderle V,
Ziegler R,
and
Nawroth PP.
Post-menopausal hormone replacement therapy and the vascular wall: mechanisms of 17 beta-estradiol's effects on vascular biology.
Exp Clin Endocrinol Diabetes
107:
477-487,
1999[ISI][Medline].
16.
Jovanovic, S,
Jovanovic A,
Shen WK,
and
Terzic A.
Protective action of 17beta-estradiol in cardiac cells: implications for hyperkalemic cardioplegia.
Ann Thorac Surg
66:
1658-1661,
1998
17.
Jun, SS,
Chen Z,
Pace MC,
and
Shaul PW.
Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium.
J Clin Invest
102:
176-183,
1999[ISI][Medline].
18.
Kauser, K,
and
Rubanyi GM.
Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae.
Am J Physiol Heart Circ Physiol
267:
H2311-H2317,
1994
19.
Kauser, K,
Sonnenberg D,
Tse J,
and
Rubanyi GM.
17
-estradiol attenuates endotoxin-induced excessive nitric oxide production in ovariectomized rats in vivo.
Am J Physiol Heart Circ Physiol
273:
H506-H509,
1997
20.
Kingma, JG, Jr,
Rouleau JR,
Magrina J,
and
Dagenais GR.
Effects of perfluorochemical hemodilution on coronary blood flow distribution in dogs.
Circulation
78:
746-753,
1988
21.
Labrie, C,
Belanger A,
and
Labrie F.
Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate.
Endocrinology
123:
1412-1417,
1988[Abstract].
22.
Legan, SJ,
Coon GA,
and
Karsch FJ.
Role of estrogen as initiator of daily LH surges in the ovariectomized rat.
Endocrinology
96:
50-56,
1975[ISI][Medline].
23.
Lindner, V,
Kim SK,
Karas RH,
Kuiper GG,
Gustaffsson JA,
and
Mendelsohn ME.
Increased expression of estrogen receptor-
mRNA in male blood vessels after vascular injury.
Circ Res
83:
224-229,
1998
24.
Luo, S,
Martel C,
Sourla A,
Gauthier S,
Merand Y,
Belanger A,
Labrie C,
and
Labrie F.
Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice.
Int J Cancer
73:
381-391,
1997[ISI][Medline].
25.
Ma, L,
Yu Z,
Xiao S,
Thadani U,
Robinson CP,
and
Patterson E.
Supersensitivity to serotonin- and histamine-induced arterial contraction following ovariectomy.
Eur J Pharmacol
359:
191-200,
1998[ISI][Medline].
26.
McCrohon, JA,
Walters WAW,
and
Robinson JTC
Arterial reactivity is enhanced in genetic males taking high dose estrogens.
J Am Coll Cardiol
29:
1432-1436,
1997[Abstract].
27.
Minshall, RD,
Miyagawa K,
Chadwick CC,
Novy MJ,
and
Hermsmeyer K.
In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones.
FASEB J
12:
1419-1429,
1998
28.
New, G,
Timmins KL,
and
Duffy SJ.
Long-term estrogen therapy improves vascular function in male to female transsexuals.
J Am Coll Cardiol
29:
1437-1444,
1997[Abstract].
29.
Node, K,
Kitakaze M,
Kosaka H,
Minamino T,
Funaya H,
and
Hori M.
Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels.
Circulation
96:
1953-1963,
1997
30.
Nuedling, S,
Kahlert S,
Loebbert K,
Doevendans PA,
Meyer R,
Vetter H,
and
Grohe C.
17
-Estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo.
Cardiovasc Res
43:
666-674,
1999
31.
Phillips, GB,
Pinkernell BH,
and
Jing TY.
Relationship between serum sex hormones and coronary artery disease in postmenopausal women.
Arterioscler Thromb Vasc Biol
17:
695-701,
1997
32.
Register, TC,
and
Adams MR.
Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta.
J Steroid Biochem Mol Biol
64:
187-191,
1998[ISI][Medline].
33.
Rodbard, D,
and
Lewald JE.
Computer analysis of radioligand assay and radioimmunoassay data.
Acta Endocrinol Suppl (Copenh)
147:
79-103,
1970[Medline].
34.
Rosano, GMC,
Sarrel PM,
Poole-Wilson P,
and
Collins P.
Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease.
Lancet
342:
133-136,
1993[ISI][Medline].
35.
Rouleau, JR,
Boerboom LE,
Surjadhana A,
and
Hoffman JIE
The role of autoregulation and tissue diastolic pressures in the transmural distribution of left ventricular blood flow in anesthetized dogs.
Circ Res
45:
804-815,
1979
36.
Rouleau, JR,
Simard D,
and
Kingma JG, Jr.
Myocardial blood flow regulation relative to left ventricle pressure and volume in anesthetized dogs.
Can J Physiol Pharmacol
77:
902-908,
1999[ISI][Medline].
37.
Smith, PJ,
Ornatsky O,
Stewart DJ,
Picard P,
Dawood F,
Wen WH,
Liu PP,
Webb DJ,
and
Monge JC.
Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats.
Circulation
102:
2983-2989,
2000
38.
Stampfer, MJ,
Colditz GA,
and
Willett WC.
Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study.
N Engl J Med
325:
175-177,
1991.
39.
Sudhir, K,
Chou TM,
Mullen WL,
Hausmann D,
Collins P,
Yock PG,
and
Chatterjee K.
Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance vessels.
J Am Coll Cardiol
26:
807-814,
1995[Abstract].
40.
Teoh, H,
Leung SWS,
and
Man RYK
Short-term exposure to physiological levels of 17
-estradiol enhances endothelium-independent relaxation in porcine coronary artery.
Cardiovasc Res
42:
224-231,
1999
41.
Thigpen, AE,
Silver RI,
Guileyardo JM,
Casey ML,
McConnell JD,
and
Russell DW.
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
J Clin Invest
92:
903-910,
1993.
42.
Van der Schouw, YT,
van der GY,
Steyerberg EW,
Eijkemans JC,
and
Banga JD.
Age at menopause as a risk factor for cardiovascular mortality.
Lancet
347:
714-718,
1996[ISI][Medline].
43.
Vlahakes, GJ,
Verrier ED,
Turley K,
and
Hoffman JIE
Maximal vascular conductance in right ventricular myocardial circulation.
Am J Physiol Heart Circ Physiol
266:
H1363-H1372,
1994
44.
Wellman, GC,
Bonev AD,
Nelson MT,
and
Brayden JE.
Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca2+-dependent K+ channels.
Circ Res
79:
1024-1030,
1996
45.
White, RE,
Darkow DJ,
and
Lang JLF
Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism.
Circ Res
77:
936-942,
1995
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |